Clinical trials: Allogeneic Stem-Cell Transplant
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Trial name
- NCT01929408
- Where
- 12 sites in United States
- Volunteers
- 703 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I
Effective treatment options for chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients with the T315I mutation are few.
- Trial name
- NCT02981784
- Testing
- Ponatinib (Iclusig®), allogeneic stem cell transplantation
- Where
- France
- Volunteers
- 184 people
- Sponsor
- Hospices Civils de Lyon
Multiple Myeloma, Myeloma-Multiple
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma
The purpose of this study is to develop a novel platform for allo-SCT in multiple myeloma (MM) with the idea of maximizing anti-myeloma effect with conditioning and minimizing GvHD (graft versus host disease).
- Trial name
- NCT02447055
- Testing
- Tocilizumab, Melphalan, Fludarabine
- Sponsor
- Washington University School of Medicine
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase I trial studies the side effects of vaccine therapy in preventing cytomegalovirus (CMV) infection in patients with hematological malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01588015
- Testing
- tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
HIV
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
To find out if it is possible for HIV-1 patients to maintain antiretroviral medications during allogeneic bone marrow transplant
- Trial name
- NCT01836068
- Testing
- Enfuvirtide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00816413
- Testing
- cyclosporine, mycophenolate mofetil, pentostatin
- Sponsor
- University of Nebraska
Acute Myeloid Leukemia
Haplo-SCT vs ASCT With or Without Decitabine in AML CR1
A multicentre, prospective, open-label clinical study, including a randomized controlled study in low or intermediate-risk group patients, and a cohort study of maintenance treatment with decitabine after ASCT.
- Trial name
- NCT02059720
- Testing
- HSCT
- Where
- China
- Volunteers
- 212 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
The hypothesis of this study is that lenalidomide can be an effective drug in preventing relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q after allogeneic HSCT.
- Trial name
- LENAMAINT (NCT00720850)
- Testing
- lenalidomide
- Where
- 7 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Technische Universität Dresden
Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)
PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood
In this prospective study is to examine whether the use of everolimus in patients after allogeneic SCT as part of GVHD prophylaxis for a further review in clinical studies is appropriate.
- Trial name
- NCT01509560
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
This phase Ib trial tests the safety, side effects, best dose and effectiveness of tagraxofusp in combination with azacitidine as maintenance therapy in treating patients with CD123 positive acute myeloid leukemia (AML) and…
- Trial name
- NCT06498973
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- City of Hope Medical Center
Myeloid Malignancies
Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies
The goal of this single-arm phase II study is to test in patients with non-remission myeloid malignancies undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
- Trial name
- NCT05807659
- Testing
- fractionated busulfan-based conditioning regimen
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sichuan University
Stem Cell Transplant, Allogeneic
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
Participants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant.
- Trial name
- EXCESS (NCT01189786)
- Testing
- CliniMACS CD34 Reagent system
- Where
- 2 sites in United States
- Volunteers
- 241 people
- Sponsor
- Baylor College of Medicine
Measurable Residual Disease
MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse
A study on the Effectiveness of digital droplet PCR in monitoring measurable residual disease during the early period after allogeneic hematopoietic stem cell transplantation to predict patients at high risk of relapse
- Trial name
- NCT06000306
- Testing
- Digital Droplet PCR
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Zhejiang University
Poor Graft Function, Myelodysplastic Syndromes
Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT
Preclinical evidence indicates that IL-1 inflammatory signaling suppresses bone marrow mesenchymal stromal cells (MSCs) from secreting stem cell factor (SCF), leading to failure of their hematopoietic supportive capacity, and…
- Conditions
- Poor Graft Function, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT07888348
- Testing
- Anakinra
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ruijin Hospital
Acute GVH Disease
MTX and Steroid as First-line Therapy for aGVHD
The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid as first-line therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation…
- Trial name
- NCT04960644
- Testing
- MTX, Corticosteroid
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
HSCT from an allogeneic donor is the standard therapy for high-risk hematopoietic malignancies and a wide range of severe non-malignant diseases of the blood and immune system.
- Conditions
- Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, in Relapse, High Risk Acute Lymphoblastic Leukemia
- Trial name
- NCT05066958
- Testing
- boost anti-viral immunity after T-cell depleted HSCT
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Lymphoma
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
This research study is assessing the feasibility of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) as a possible treatment for relapsed / refractory non-Hodgkin lymphoma involving the central nervous…
- Trial name
- NCT02724904
- Testing
- Allogeneic stem cell transplantation, Fludarabine, Thiotepa
- Where
- 2 sites in United States
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
This is a single-arm, Phase II study of crenolanib as maintenance in AML patients with FLT3 mutations who have achieved complete remission (CR) after allogeneic stem cell transplantation.
- Trial name
- NCT02400255
- Testing
- Crenolanib besylate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Arog Pharmaceuticals, Inc.
AML, ALL
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Allogeneic stem cell transplantation may provide long-term remissions for some patients with hematological malignancies. However, allogeneic transplantation is associated with a significant risk of potentially life threatening…
- Conditions
- AML, ALL, CLL, Myelodysplastic Syndrome
- Trial name
- NCT00533923
- Testing
- Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Neuroblastoma
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.
RATIONALE: - Relapsed or refractory Neuroblastoma (NBL) carries a very poor prognosis and children with relapsed NBL have an overall 3 year survival rate of < 10%.
- Trial name
- NCT00874315
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- 4 sites in United States
- Sponsor
- Nationwide Children's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.